[ad_1]
The first drug designed to prevent migraine headaches may be available soon after approval by European authorities.
Known as Erenumab and Aimovig, the drug will now be reviewed by the health authorities of England and Scotland.
Even though it was denied by public health officials, the manufacturer Novartis said that patients would be able to access drugs privately from September.
It is designed to block a brain receptor called the peptide receptor, which is supposed to be involved in the activation of migraines – although scientists are still not completely sure of what causes distressing headaches.
The European Medicines Agency has approved the drug for patients with at least four migraines per month. and patients will self-administer at home with a pen injector
The drug has been licensed for patients who suffer from four migraines a month
009] In drug trials, it has been shown that the average number of migraine days in a month was halved.
"Erenumab is the first and only authorized treatment specifically designed to prevent migraine headaches," said Haseeb Ahmad, British director of Novartis, about innovative therapies for people suffering from some of the most severe conditions. Debilitating: "We think this decision is wonderful, Wendy Thomas, General Manager of Migraine Trust, as this new treatment has the potential to help many people with chronic and episodic migraine."
"Migraine is incredibly painful and presents with symptoms such as vomiting and visual disturbances, so getting it frequently can literally ruin lives
.That's why it's important that it be available to patients as soon as as possible. "
Source link
